Trump Disclosure Shows Corcept Buy Before FDA Approval

By: Quiver EventTracker

Posted: 21 hours ago / July 20, 2026 5:37 p.m. UTC

CORT

A public financial disclosure by President Donald Trump shows a $50,001-to-$100,000 purchase of Corcept Therapeutics stock on March 3rd, 2026, weeks before the FDA approved Corcept’s ovarian-cancer drug Lifyorli on March 25.

Disclosure: Quiver Quantitative lists the Corcept purchase as a Trump transaction dated March 3rd and disclosed May 13. Source

Reporting rules: OGE Form 278-T covers securities purchases, sales or exchanges over $1,000 made on behalf of the filer, spouse or dependent child. Source

FDA action: The FDA approved Lifyorli with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Source

Relevant Companies

Corcept Therapeutics (CORT): Directly impacted by Lifyorli approval and related investor attention.

Add Quiver Quantitative to your preferred sources on Google

Suggested Articles

Apple to Launch ‘Apple Upgrade’ Leasing Program With Klarna Backing July 21, 2026 3:28 p.m. UTC

Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims July 21, 2026 1:30 p.m. UTC

With caps on party spending removed, how could campaign finance activity change? July 20, 2026 7:01 p.m. UTC